|
|
Article: Horizon's 'GI-Friendly' NSAID Work Backed By $30M Series C.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Privately held Horizon Therapeutics Inc. raised $30 million in venture capital, securing adequate funding to complete two ongoing Phase III studies of lead product HZT-501, an NSAID combined with a gastroprotective agent, in patients suffering mild to moderate pain.
Essex Woodlands Health Ventures, of Palo Alto, led the Series C round, with participation from existing investors Scale Venture Partners, of Foster City, Calif., Sutter Hill Ventures, also of Palo Alto, and Pequot Ventures, of New York. Horizon, which previously brought in $15 million in Series B round in the fall, has raised a total of $51 million to date.
The latest ...